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Summary points
• According to current estimates, 36.7 million people are infected with HIV worldwide.
Despite large-scale and growing programs to prevent and treat HIV infection, possible
approaches to achieve a cure for HIV infection are of strong interest.
• In the development of candidate approaches to achieve an HIV cure, issues of future
translation to human study participants, evidence-based practice, clinical care, diverse
populations, and populations in low- and middle-income countries should all be
considered.
• An HIV cure should be effective, safe, simple, affordable, and scalable.
• Acceptability research is a critical adjunct to ongoing biomedical HIV cure research
efforts.
• Anticipating some of the ethical and implementation challenges related to HIV cure
strategies is necessary before the availability of effective interventions.
• Ongoing engagement of stakeholders is needed to resolve ethical, logistical, social, cul-
tural, policy, regulatory, and implementation challenges at all stages of the HIV cure
research development process.
OPENACCESS
Citation: Dube´ K, Sylla L, Dee L, Taylor J, Evans D,
Bruton CD, et al. (2017) Research on HIV cure:
Mapping the ethics landscape. PLoS Med 14(12):
e1002470. https://doi.org/10.1371/journal.
pmed.1002470
Published: December 8, 2017
Copyright:© 2017 Dube´ et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Funding: NIH grant R01A108366 (Social and
Ethical Aspects of Research on Curing HIV,
searcHIV) supported this work. BB received
support from a NIH diversity supplement
(3R01AI114617-03S1). The funders had no role in
study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing interests: The authors have declared
that no competing interests exist.
Abbreviations: ART, antiretroviral therapy; ATI,
analytical treatment interruption; FDA, Food and
Drug Administration; FIH, first-in-human; HDAC,
histone deacetylase inhibitor; IND, Investigational
New Drug; PLWHIV, people living with HIV; PrEP,
preexposure prophylaxis.
Provenance: Not commissioned, externally peer-
reviewed.
There are approximately 36.7 million people living with HIV (PLWHIV) worldwide, and
around 1.1 million people died of HIV/AIDS-related complications in 2015 [1]. Global scale-
up of HIV antiretroviral therapy (ART) contributed to a 48% reduction in AIDS-related mor-
tality between 2005 and 2016 [2]. Nonetheless, ART does not remove replicative HIV from the
body and is not a cure [3]. Without a cure, HIV will remain a chronic infection with the poten-
tial to cause and spread lethal disease. Until the Berlin patient’s HIV cure in 2008 [4], a cure
for HIV remained inconceivable. The Berlin patient’s cure revived interest in identifying strat-
egies that could lead to long-term remission or elimination of HIV. The Food and Drug
Administration (FDA) defines HIV cure research as “any investigation that evaluates: (1) a
therapeutic intervention or approach that controls or eliminates HIV infection to the point
that no further medical interventions are needed to maintain health; and (2) preliminary
scientific concepts that might ultimately lead to such a therapeutic intervention [5].” HIV cure
studies occur at various stages of the translational research continuum, from basic scientific
discoveries in a laboratory to clinical applications with human participants. As the goal of HIV
cure research is to identify regimens that are “effective, simple, safe, and scalable” [6], it will be
important to bridge the gap between current basic cure research and the future implementa-
tion of cure regimens in clinical practice. In doing so, we must consider ethical issues related
to the translation of discoveries from animal models to human participants and future imple-
mentation of curative interventions into real-world clinical settings, an area of limited focus in
the ethics literature. This paper builds on the emerging HIV cure research ethics [7] to identify
key ethical and implementation issues at each stage of the translational research continuum
that are distinctive to HIV cure research. We highlight key potential ethical and implementa-
tion issues for HIV cure research developers, regulators, and policy makers.
Translational research continuum and translational ethics
Khoury and colleagues developed a classification framework for translational research that is
divided into 4 categories: T0, preclinical research; T1, translation of discoveries to humans; T2,
translation of findings to evidence-based practice; T3, translation of interventions to clinical
practice; and T4, transition of interventions to improve population health [8]. The T0–T4
translational research continuum provides a unifying framework bridging the range of HIV
cure scientific discoveries, human application, advancement into clinical practice, and work
towards global HIV cure. We apply this continuum for our analysis of the ethical and imple-
mentation issues related to translational HIV cure research. Kagarise and Sheldon are credited
with proposing the concept of “translational ethics,” which aims to help stakeholders “navigate
the ethical ramifications of technological and scientific advances [9].” Translational HIV cure
research will require not only the transfer of discoveries into interventions to improve the lives
of PLWHIV but also the effective and responsible translation of interventions into clinical
practice and public health [10].
T0: Preclinical HIV cure research
Most current HIV cure experiments occur in the preclinical (T0) research stage and involve
genes, mechanistic pathways, cell lines, and animal models [11]. Significant advancements in
HIV treatment, together with increased understanding of animal models for HIV research,
have enabled the development of animal models to study HIV persistence and how HIV
remains latent inside cells [12]. Nonhuman primates, including rhesus and pigtail macaques,
and humanized mice that mimic human immune functions provide useful models to answer
scientific questions that inform HIV cure research [12]. Animal models can also allow for con-
trol of key variables such as virus dose, route of infection, and host genetics, all of which
contribute to infection outcomes. The design of animal model experiments should be scientifi-
cally sound to augment the chance that they will be able to predict intervention effectiveness in
human studies [13]. This includes ensuring proper sample sizes, applying randomization and
blinding, and defining inclusion/exclusion criteria with animal models [13]. There also need
to be basic evidentiary thresholds for animal models before interventions are applied to
humans [14]. HIV cure scientists must further pay attention to animal research ethics issues,
in the context of animals’ intrinsic value and moral rights and independent of their utility in
preclinical HIV cure research [15]. The basic tenet of ethical research using animals involves 3
Rs: “reduce the number of animals used to the minimum necessary for meaningful results,
refine procedures to minimize pain and other burdens, and replace whole-animal experiments
with in vitro models or experiments with less sentient organisms whenever possible [16].”
The ethical issues described above are not unique to HIV cure research. What is notable,
however, is the pace and scale of preclinical HIV cure research at this time in history, given the
significant investments from funders in finding a cure for HIV.
T1: Translating HIV cure discoveries to humans
The T1 level of translation involves transferring preclinical discoveries to first-in-human
(FIH) studies involving Investigational New Drug (IND) applications [8]. These include new
investigational approaches to curing HIV (such as gene therapy or stem cell transplants), as
well as repurposed drugs (e.g., compounds borrowed from oncology) or novel drugs and bio-
logics advanced from animal models. HIV cure studies face many of the ethical dilemmas sur-
rounding other early-phase research, such as oncology [17]. One key difference, however, is
that most HIV cure experiments occur in volunteers who are “otherwise healthy” [18]. HIV
cure research is usually conducted among individuals on highly effective and safe antiretroviral
therapy, many of whom enjoy an almost normal life expectancy [19]. One of the major ethical
issues relates specifically to the high risk of investigational interventions and the correspond-
ing low prospect of direct clinical benefit [20]. HIV cure researchers must make all efforts pos-
sible to minimize risks while maximizing the social value of cure studies.
The high risks and minimal prospects for personal clinical benefits of HIV cure research
further highlight the significance of a comprehensive informed consent process that distin-
guishes between benefits to society and benefits to individual participants [21]. The informed
consent process must clearly state that HIV cure research is experimental [20], the limited
prospect for personal clinical benefits, the unique requirements for the research, and the asso-
ciated risks, as well as the compensation for research-related injury. In terms of risks, the
informed consent process should also make clear any distinctions between risks due to the
research modality itself or to monitoring procedures and/or those associated with analytical
treatment interruptions (ATIs) [7]. Further, an effective HIV cure will likely require a combi-
nation of approaches with the potential of compounding clinical risks beyond those associated
with current antiretroviral therapy [22], such as psychosocial, legal, social, and economic risks
[23].
In alignment with the principle of distributive and representational justice [24], the selec-
tion of HIV cure study participants should remain fair and equitable [7]. Participants in HIV
cure research should represent the population of those living with HIV. Inclusion of people of
color, women, transgender individuals, and underrepresented minorities in sufficient num-
bers to achieve statistical power to detect clinical differences is important since gender and
genetic differences may affect the biology of curing HIV. Excluding certain populations at
early stages may limit results of later stages of translational research [25]. To date, these impor-
tant subgroups have remained underrepresented in research in general and specifically in HIV
cure research [26]. Biomedical HIV cure researchers should engage communities to better
understand barriers to subgroup enrollment in clinical studies and inform strategies to
encourage greater participation of underrepresented groups [27]. Further, efforts should be
made to overcome the challenges of implementing HIV cure research in low- and middle-
income countries [28], such as limited clinical and laboratory research capacity, shortages of
trained staff, restricted financing, and more fragile healthcare systems [29].
Moreover, HIV cure research encompasses several different HIV cure strategies [30]. Each
strategy would benefit from the availability of specific criteria to be used to judge ethical per-
missibility. For example, Shah argues that experimental stem cell transplantations should not
be conducted in children because of the relatively high risks [31]. Sugarman provides consider-
ation for when ART interruption following stem cell transplantation would be ethically appro-
priate [32]. Future work is needed to create ethical guidelines across types and combinations
of HIV cure research strategies. Finally, ATIs remain one of the most controversial topics in
HIV cure research that combines considerations for medical, research, and public health eth-
ics. Scholars have provided scientific and ethical considerations related to ATIs, including par-
ticipant selection, informed consent, community engagement, and public perceptions of ATIs
[33,34].
T2: Translation of findings to evidence-based practice
The T2 level of translation refers to late-phase clinical trials, observational studies, and guide-
line development [8]. There are few Phase II and III HIV cure clinical trials at present [30].
Further, there are limited validated biomarkers to predict the effects of HIV cure research
interventions. The field of HIV cure research could benefit from better harmonization of HIV
reservoir assessments and biomarkers and endpoints, within and across types of HIV cure
research strategies. The field could also benefit from clear criteria warranting ATIs and bench-
marks to define remission success following ATIs [35]. Virologic rebound cannot be predicted
during ATIs [36]. Thus, studies involving ATIs must include proper informed consent and
frequent virological monitoring. Third-party risks, such as secondary transmissions due to
unpredictable relapses of viremia, should be minimized. Adequate standard of prevention
packages for the sexual partners of study participants, including information on preexposure
prophylaxis (PrEP) or other effective preventive methods [34], should be offered, and suffi-
cient privacy protections should be in place.
A key indicator of HIV cure effectiveness will be the identification of objective biological
markers for long-term virological suppression or elimination off therapy. We must define the
correct timeframe off ART before we can pronounce a participant cured of HIV. Borrowing
the concept of remission from the cancer field [37], a 5-year benchmark for remission is con-
sidered a cure in cancer and is being considered by some as a standard for a functional HIV
cure.
Another topic of interest in the translation of findings to evidence-based practice will be the
substantial level of risk monitoring involved in HIV cure studies. Most interventions carry
risks above those of standard ART. For example, histone deacetylase inhibitors (HDACs), a
class of latency-reversing agents, can be mutagenic, teratogenic, or genotoxic and may raise
concerns among participants about long-term risks of cancer and warrant long-term follow-
up monitoring of study participants [38,39].
Biomedical HIV cure trialists must ensure the acceptability of interventions to PLWHIV.
The best way to do this is to involve them early on in formulating interventions. Attributes
of the interventions will be factors in decisions of PLWHIV to participate and contribute to
statistical study power in late-phase efficacy trials. It is not premature to begin assessing
hypothetical and actual acceptability of HIV cure interventions with the goal of refining prom-
ising HIV cure interventions so that they can be acceptable to PLWHIV [40]. Failure to con-
duct such assessment may lead to the development of HIV cure research approaches that are
unappealing to PLWHIV or otherwise impossible to implement. Thus, acceptability research
is a critical adjunct to ongoing biomedical HIV cure research efforts [41].
In addition to study participant acceptability, it is also important to ensure the acceptability
of the research and proposed interventions within the larger community. By community, we
mean “a group of people with diverse characteristics who are linked by social ties, share com-
mon perspectives, and engage in joint action in geographical locations or settings [42].” There
is a need for robust community engagement efforts as early as possible in the translational
HIV cure research continuum for both PLWHIV and those affected by the epidemic.
T3: Translation to clinical practice
The T3 level of translation refers to the transfer of effective interventions to clinical practice.
T3 also includes implementation research and phase IV clinical trials [8]. At the T3 stage of
translation, opinion leader approval is paramount. In the HIV cure research field, there
remains a dearth of robust social sciences research around perceptions of HIV care providers
[43]. If HIV clinicians are not on board with HIV cure interventions, it is unlikely that patients
will receive them. For example, HIV care provider buy-in is one of the facilitators for PrEP
uptake in some populations, along with cost and other access issues, as well as considerations
about effectiveness and side effects [44]. Further, issues of availability (physical access) and
affordability (financial access) of the intervention become prominent at this stage. The HIV
cure research field should address the economics of equitable distribution of a cure for HIV.
The high costs initially associated with hepatitis C cure inform us of the importance of inte-
grating access factors early in HIV cure development. It would be unethical to deny PLWHIV
in the United States and abroad access to a future approved HIV cure because of pricing con-
straints. Legislators, policy makers, insurance companies, and HIV activists should partner in
efforts to ensure that any future HIV cure approaches are accessible to PLWHIV without pric-
ing constraints, especially with regards to low- and middle-income countries [28].
The implications for sexual partners of individuals undergoing curative interventions must
also be considered. Of particular concern is the potential for infectivity in the case of viremic
rebound [34] and the risk of behavioral disinhibition related to the idea of individuals no lon-
ger having HIV and considering themselves uninfectious, possibly leading to secondary infec-
tions. PLWHIV will also need to weigh their prospects of a lifetime on antiretroviral therapy
[45] versus the potential consequences of undertaking HIV curative regimens. The quality of
life of individuals who undergo such HIV cure interventions will need to be monitored regu-
larly, in many cases for years to come. Economic risks of cure will also need to be taken into
considerations, such as the possible loss of disability insurance or income [23]. A cure for HIV
will likely not reverse the cumulative damage from years or decades of viremia and treatment.
Thus, a subset of long-term survivors may have ongoing clinical and psychological issues
despite HIV remission or elimination. Further, the possibility of reinfection and eligibility for
“second” cures will need to be considered, as it may affect resource allocation decisions as well
as HIV prevention efforts.
Finally, at the T3 translation level, implementation research can help determine the best way
to operationalize a cure in the real world. We define implementation research as “the study of
methods to promote the uptake of research findings into routine practice [46].” While imple-
mentation research for HIV cure may seem like a far-fetched and speculative agenda, an effec-
tive HIV cure will require a coordinated and integrated approach through all stages of research.
T4: Translation to improve population health
The T4 level of translation refers to the application of effective interventions to improve popu-
lation health [8]. If an HIV cure strategy proves successful, a comprehensive rollout strategy
that accounts for the ability to scale-up the interventions will be necessary. The scalability of
an HIV cure is a key topic in translational ethics, as it refers to the absorptive capacity of
healthcare settings to adopt the intervention into existing systems [47]. Scalability must be a
key factor in assessing the social value of specific HIV cure research strategies. Efforts are
underway to make some HIV cure research approaches more scalable, such as “gene therapy
in a box” [48]. To ensure implementation feasibility of an HIV cure around the world, chal-
lenges of healthcare worker shortages, limited laboratory capacity and access, financing, qual-
ity monitoring, public reluctance to accept new technologies, and priority setting for high-cost
interventions will also need to be surmounted [29].
In the context of population health interventions, allocation of scarce resources between
HIV prevention, treatment, and HIV cure research represents a translational ethics issue. Fair
allocation relates to the principles of distributive justice and responsiveness to global health
priorities. Approximately 1.8 million new HIV infections [2] occur each year, and HIV testing
and prevention remain important, along with universal HIV treatment for PLWHIV [45]. We
have a long way to go in bridging gaps in the HIV treatment continuum worldwide [49].
Development of an HIV cure should closely synergize with ongoing efforts to prevent and
treat HIV infection and raise the bar for the entire field of HIV control. For example, HIV
cure researchers can work with PrEP clinics to identify acutely infected individuals who may
be HIV cure study candidates, although early treatment would restrict, but not prevent, estab-
lishment of HIV reservoirs [50]. Moodley and colleagues similarly advocated for a symbiotic
relationship between HIV prevention, treatment, and cure in resource-limited settings [51].
Table 1 summarizes some of the considerations for translating HIV cure research discover-
ies from the T0–T4 stages of translation.
Conclusion
Tremendous human, financial, and social capital is being invested in the discovery of an HIV
cure. For an HIV cure regimen to prove valuable, it should be effective, safe, simple, affordable,
and scalable [29]. It should also be translatable to human study participants, evidence-based
Table 1. Considerations for translation of HIV cure research discoveries.
Phases of translation Considerations
T0: Preclinical research (animal models in HIV
cure research)
• The design of animal model experiments should be
scientifically sound so that scientists can predict
intervention effectiveness in human studies
• Basic evidentiary thresholds for animal models are
needed before interventions are applied to humans
T1: Translation of HIV cure research
discoveries to humans (first-in-human studies)
• There is a high risk of investigational interventions
and a corresponding low prospect of direct clinical
benefit to study participants
• There should be a robust informed consent process
that distinguishes between benefits to society and
benefits to individual participants
• The selection of HIV cure study participants should
remain fair and equitable (i.e., inclusion of
underrepresented minorities)
• Ethical guidelines should be created across types
and combinations of HIV cure research strategies
(Continued )
practice, clinical care, and diverse populations. Appreciating the inherent translational ethics
issues across the entire research continuum is essential, as HIV cure discoveries must eventu-
ally translate to real-world implementation. In this paper, we reviewed some of the consider-
ations at each step of the HIV cure translation and implementation continuum; the issues
described are not comprehensive. We asserted that an ethics of translation should begin early
in the HIV cure discovery effort, before the availability of efficacious interventions. Logistical,
social, cultural, and economic issues will affect the implementation of HIV cure research and
interventions at the individual, institutional, national, and global levels. Ongoing community
and stakeholder engagement efforts will be crucial to foresee, negotiate, and resolve potential
ethical and implementation challenges. Innovative translational and implementation research
paradigms utilized at all phases of the HIV cure research continuum will permit us to address
critical issues that will ultimately help leverage cutting-edge HIV cure research discoveries to
benefit PLWHIV around the globe.
Table 1. (Continued)
Phases of translation Considerations
T2: Translation of findings to evidence-based
practice (late-phase trials, observational studies,
and guideline development)
There is a need for the following:
• Better harmonization of HIV reservoir assessment,
biomarkers, and endpoints within and across types of
HIV cure research strategies
• Clear criteria warranting analytical treatment
interruptions (ATIs) and benchmarks to define
remission success following ATIs
• Proper informed consent and frequent virological
monitoring for procedures involving ATIs
• Standard of prevention packages for the sexual
partners of HIV cure study participants
• Adequate acceptability research and involvement of
people living with HIV (PLWHIV) in formulating
interventions
• Data collection on implementation costs, training
requirements, and other critical translational and
implementation issues
• Robust community engagement efforts as early as
possible in the translational research process
T3: Translation to clinical practice (transfer to
clinical practice, implementation research, and
phase IV clinical trials)
• Opinion leaders’ approval (e.g., HIV care providers)
will be paramount
• Legislators, policy makers, insurance companies,
and HIV activists should anticipate challenges related
to the economics of equitable distribution of a cure for
HIV
• The quality of life of individuals who undergo HIV
cure interventions will need to be carefully monitored
• The possibility of reinfection and eligibility for
“second” cures will need to be considered, as it may
affect resource allocation decisions and HIV
prevention efforts
T4: Translation to improve population health
(application of effective interventions to
populations)
• Scalability should be a key factor in assessing the
social value of specific HIV cure research strategies
• There is a need to anticipate implementation
feasibility issues for a global HIV cure, including
healthcare worker availability, laboratory capacity,
financing, and quality issues
• There is a need to consider the allocation of scare
resources between HIV prevention, treatment, and
HIV cure research
• Development of an HIV cure should align with and
raise the bar for the entire field of HIV control
https://doi.org/10.1371/journal.pmed.1002470.t001
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